#### Company Overview
SMS Lifesciences India Limited, established in 1990 and headquartered in Hyderabad, India, is a significant player in the pharmaceutical sector. It originated as the demerged entity of SMS Pharmaceuticals Ltd and specializes in catering to semi-regulated markets across India, Europe, and Asia. The company's core business involves manufacturing a portfolio of 12 APIs primarily in the GAS (Gastrointestinal and Anti-ulcer) and Anti-erectile dysfunction (EDF) therapeutic segments. Originally incorporated as Potluri Real Estate Private Limited on May 31, 2006, its name evolved through Potluri Packaging Industries Private Limited (November 6, 2013) before becoming SMS Lifesciences India Private Limited on August 4, 2014, to focus on pharmaceutical activities.
The company's shares were listed on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) effective August 17, 2017, following the allotment of 3,023,287 equity shares of ₹10 each to the shareholders of SMS Pharmaceuticals Limited (the transferor company) on June 27, 2017, in pursuance of a demerger scheme.
#### Business Operations and Products
SMS Lifesciences India Limited is engaged in the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and intermediates within India and globally. The company's extensive product range covers multiple therapeutic areas, including anti-ulcer, erectile dysfunction, anti-gout, anesthesia, anti-infective, anti-obesity, antifungal, anti-convulsant, anti-emetic, ophthalmic, anti-worm, and anti-emetic. Furthermore, SMS Lifesciences is actively involved in the development of APIs for antidepressant, antipsychotic, anti-hypertension, veterinary, antiviral, and anticoagulant applications. The company also produces intermediates for a wide array of therapeutic segments such as anti-ulcer, anti-migraine, anti-hypertension, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-gout, anti-infective, anti-convulsant, antiviral, and anesthesia.
With robust research and manufacturing capabilities supported by state-of-the-art facilities, SMS Lifesciences operates as a global player in APIs and intermediates. The company possesses manufacturing facilities located in Kazipally and Jeedimetla, Hyderabad, boasting an installed capacity of 65 KL. It operates three multi-product facilities and a dedicated research centre, enabling it to undertake contract manufacturing and research assignments for a diverse international clientele.
#### Manufacturing Capacity and Subsidiaries
Mahi Drugs Private Limited became a wholly-owned subsidiary of SMS Lifesciences India Limited effective September 17, 2018, following the company's acquisition of 900,000 equity shares. However, its status changed when SMS Lifesciences diluted its stake by 10% during FY2021-22, and Mahi Drugs Private Limited ceased to be a wholly-owned subsidiary from February 7, 2022.
In terms of production, the company achieved a significant milestone in FY2019 by producing 2,040 metric tons (M.T.) of APIs and their intermediates, an increase from 1,729 M.T. recorded in FY2017-18.
#### Market Capitalization and Stock Performance
As of July 2025, SMS Lifesciences India Limited reported a market capitalization of ₹402.66 crore. Different sources show slightly varying figures depending on the reporting date, with market cap estimates around ₹350.12 Cr (June 16, 2025) and ₹352 Cr (June 13, 2025). Based on Value Research classification, SMS Lifesciences India Ltd is categorized as a Small Cap company.
The stock has demonstrated notable volatility. Its 52-week high reached ₹1,747.85 per share, while the 52-week low was recorded at ₹765 per share. Over the past six months, the share price has seen a decrease of 13.27%, whereas over the last year, it has experienced a substantial increase of 100.65%.
#### Shareholding Pattern
The promoter holding in SMS Lifesciences India Ltd has shown a slight upward trend, increasing to 71.41% as of December 2024 from 71.19% as of March 2024. The current promoter holding stands at approximately 71.4%.
#### Recent Financial Performance
Full Year FY2025 Performance:
- Net Profit: Rose by 121.23% to ₹20.11 crore for the year ended March 2025, compared to ₹9.09 crore in the previous year ended March 2024.
- Sales: Increased by 12.67% to ₹344.72 crore for the year ended March 2025, up from ₹305.96 crore in the previous year ended March 2024.
Quarterly Performance (Q4 FY2025):
- Net Profit: Declined by 49.66% to ₹2.97 crore in the quarter ended March 2025, from ₹5.90 crore in the corresponding quarter of the previous year ended March 2024.
- Sales: Decreased by 0.98% to ₹89.11 crore in the quarter ended March 2025, compared to ₹89.99 crore in the quarter ended March 2024.
Key Financial Metrics:
- Annual Revenue: ₹346 Crore (FY2025)
- Annual Profit: ₹21.7 Crore (FY2025)
- P/E Ratio: 17.41
- P/B Ratio: 1.81
- Dividend Yield: 0.13%
#### Awards and Recognition
SMS Lifesciences India Limited has been recognized for its contributions to the pharmaceutical industry, including:
- "India Pharma Bulk Drug Company of the Year Award" from the Government of India (2020).
- "Outstanding Export Performance Award 2018-19" in the "All round-Rising Star" Category from The Pharmaceuticals Export Promotion Council of India.
#### Recent Regulatory Developments
In a significant development, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status for its API manufacturing facility (Unit 1) located at Kazipally, Telangana, from the U.S. Food and Drug Administration (USFDA). This report was received on July 15, 2025. This positive regulatory outcome led to a notable market reaction, with SMS Lifesciences India shares hitting a 20% upper circuit on the BSE at ₹1,372.55 per share.
#### Recent Corporate Changes
For FY2025, the company announced its audited results, recommending a dividend of ₹1.50 per share. The board also approved a proposed name change to Haleos Labs and the reappointment of a director.
SMS Lifesciences India Limited continues to solidify its position as a specialized pharmaceutical company focused on API manufacturing. It serves both domestic and international markets while prioritizing strong regulatory compliance across all its manufacturing facilities.
